United States Patent 10,034,841: Transdermal Therapeutic System Scope, Claim Analysis, and Patent Landscape

U.S. Patent No. 10,034,841 protects a multilayer transdermal patch architecture using an ultrathin, crosslinked silicone anchor layer between a backing film and a silicone-adhesive drug-containing polymer layer. The central limitation is a siliconized anchor layer that is firmly attached to the backing, adheres to the drug-containing layer, contains vinyl-functional and Si-H-functional organopolysiloxanes, and is less than 10 micrometers thick.

The patent is a platform and formulation-construction patent rather than a patent directed to one identified active pharmaceutical ingredient. Its practical value depends on whether a competing patch uses the claimed layer sequence and silicone chemistry. The claims do not expressly require a specific drug, dose, release rate, therapeutic indication, or marketed product.

What does U.S. Patent 10,034,841 cover?

The patent covers a transdermal therapeutic system having three required layers in a defined spatial order:

A backing layer.
A siliconized anchor layer.
A polymer layer containing a silicone adhesive and an active ingredient.

The anchor layer is the technical center of claim 1. It must satisfy all of the following requirements:

Claim 1 limitation	Scope
Backing layer	Any backing layer compatible with the claimed system, subject to the dependent claim examples
Siliconized anchor layer	A separate intermediate layer between the backing and drug-containing polymer layer
Firm attachment to backing	The anchor must be firmly anchored to the backing layer
Adhesion to polymer layer	The anchor must adhere to the polymer layer
Silicone chemistry	Vinyl-containing organopolysiloxanes crosslinked with organopolysiloxanes containing Si-H groups
Thickness	Less than 10 micrometers
Polymer layer	Contains silicone adhesive and at least one active ingredient

The claim is not satisfied by a conventional silicone adhesive drug matrix alone. A competing product must have the claimed intermediate siliconized anchor layer, or an equivalent structure potentially subject to the doctrine of equivalents.

The wording supplied for claim 1, "silicone adhesive acid active ingredient," is grammatically ambiguous. The technically coherent reading is likely "silicone adhesive and active ingredient." The issued patent, its specification, and the prosecution history control the legally operative construction, not a paraphrased claim transcription.

How strong is the independent claim?

Claim 1 is narrow in architecture but broad in drug coverage.

Its breadth comes from the absence of a limitation identifying:

A particular active ingredient.
A specific drug concentration.
A particular therapeutic indication.
A defined drug flux.
A particular silicone adhesive grade.
A specified backing material.
A defined release profile.
A required surface area or patch shape.

Its limitations are narrow because the accused system must have:

A separate anchor layer.
A silicone-based anchor chemistry.
Crosslinking between vinyl-functional and Si-H-functional organopolysiloxanes.
A thickness below 10 micrometers.
The specified layer order.

A patch with a silicone adhesive matrix directly attached to the backing layer would generally fall outside the literal wording of claim 1 because it lacks the separate anchor layer. A patch using an acrylic or polyisobutylene anchor layer would also lack the expressly required silicone anchor chemistry.

Literal-infringement profile

The strongest literal-infringement case would involve a patch with:

A polyester or polyethylene terephthalate backing.
A primer or silicone anchor coating below 10 micrometers.
A silicone adhesive drug matrix.
A removable release liner.
A polar backing or a backing that prevents adhesive overhang.

The most important evidence would be manufacturing records, coating specifications, cross-sectional microscopy, Fourier-transform infrared analysis, silicone chemistry records, and layer-thickness data. Finished-product inspection alone may not reveal whether the anchor layer is present or whether it absorbs active ingredient.

What do claims 2 through 11 add?

Claims 2 through 11 narrow claim 1 through materials, construction, and product configuration.

Claim	Added limitation	Commercial significance
2	Backing selected from polyester, polypropylene, polyethylene, polyurethane, EVA/polyester combinations, polyvinylidene chloride, polyaramid, or ethylene-(meth)acrylate copolymer	Covers common flexible pharmaceutical backing films
3	Polyethylene terephthalate backing	Important for common PET-backed patches
4	Alternative backing materials including ethylcellulose, cellulose acetate, cellophane, paper, metal-polymer composites, and EVA	Expands material coverage outside the claim 2 list
5	Silicone adhesive is a polysiloxane or polysiloxane mixture	Narrows the adhesive chemistry
6	Polymer layer is self-adhesively connected to the anchor layer	Targets direct adhesive bonding between the matrix and anchor
7	Detachable protective layer	Covers a conventional release liner
8	Anchor layer absorbs no active ingredient	Excludes drug-loaded anchor layers and strengthens manufacturing distinction
9	Polar backing, silicone adhesive polymer layer, and no adhesive overhang	Targets edge-control and clean patch construction
10	Anchor consists of vinyl-containing organopolysiloxanes and Si-H-containing organopolysiloxanes	Restates and narrows the crosslinked silicone chemistry
11	Polymer layer adheres to the detachable protective layer	Covers the release-liner interface

Claims 3, 5, 7, 8, 9, and 10 are the most commercially relevant dependent claims. They map closely to production specifications likely to be used in a pharmaceutical transdermal patch.

What formulations are protected by U.S. Patent 10,034,841?

The patent can cover a broad range of silicone-adhesive transdermal formulations if the patch has the claimed anchor-layer construction. The claims do not limit the active ingredient to a therapeutic class.

Potentially relevant products include patches containing:

Opioid analgesics.
Hormonal agents.
Central nervous system drugs.
Cardiovascular drugs.
Antiemetics.
Nicotine.
Anti-inflammatory agents.
Other small molecules capable of transdermal delivery.

The patent does not, based on the supplied claims, protect an active ingredient by chemical composition. It protects the delivery-system construction. A product could therefore infringe even if its active ingredient differs from the active ingredient used in an example, provided every claim limitation is met.

Does the patent protect the drug itself?

No. The claims protect a transdermal system and its physical construction. They do not claim:

The active ingredient as a molecule.
A salt, polymorph, or crystal form.
A therapeutic method using the active ingredient.
A dose regimen.
A specific indication.
A manufacturing process for synthesizing the active ingredient.

Any product-specific exclusivity would have to arise from separate compound, formulation, method-of-use, manufacturing, or regulatory patents.

What patent landscape surrounds this technology?

The relevant patent landscape has five principal categories.

Silicone adhesive matrix patents

These patents cover drug-containing silicone adhesives, silicone-compatible solubilizers, drug loading, crystallization control, and release rates. They may create blocking rights even when a competing patch avoids the claimed anchor layer.

Multilayer patch patents

These patents cover combinations of backing layers, drug matrices, primers, membranes, release liners, and adhesive overlays. They are the closest structural prior-art category to Patent 10,034,841.

Primer and anchoring patents

These patents address adhesion between low-surface-energy backings and silicone or acrylic drug matrices. Patent 10,034,841 is differentiated by the claimed ultrathin crosslinked silicone anchor layer.

Active-ingredient formulation patents

A drug-specific formulation patent may claim a particular concentration, solvent system, crystallization inhibitor, adhesive composition, or patch size. Such patents can remain relevant even if Patent 10,034,841 expires or is designed around.

Manufacturing-process patents

Manufacturing patents may cover coating, drying, curing, lamination, release-liner removal, and continuous-web production. The anchor-layer limitation creates a potential process fingerprint because it requires a controlled coating and crosslinking step below 10 micrometers.

When does U.S. Patent 10,034,841 lose exclusivity?

The patent was issued on July 31, 2018. Its enforceable term is governed by the U.S. patent-term rules applicable to its underlying nonprovisional or international application, including any applicable patent-term adjustment or extension. The expiration date cannot be derived from the patent number or the claim text alone.

Because the claims are not directed to an identified drug, the patent does not establish a drug-specific FDA exclusivity period. It is distinct from:

New chemical entity exclusivity.
New clinical investigation exclusivity.
Orphan-drug exclusivity.
Pediatric exclusivity.
Biologic reference-product exclusivity.

Patent term extension under 35 U.S.C. § 156 would generally depend on whether the patented product and regulatory approval satisfy the statutory requirements. A platform patch patent does not automatically receive an extension merely because a product using the technology obtained FDA approval.[2]

What is the Orange Book status of Patent 10,034,841?

The claims supplied do not identify an FDA-approved drug product, dosage form, or applicant-held NDA. On that record, the patent should be treated as a formulation or delivery-platform patent rather than a confirmed Orange Book-listed patent.

Orange Book listing is product-specific. A patent must be submitted by an NDA holder and must fall within the FDA’s listing categories. The existence of a patent covering a transdermal system does not itself establish that the patent is listed for any approved product.[3]

If listed against an NDA, the patent could affect an ANDA applicant through a Paragraph IV certification. If not listed, it would not create the same statutory ANDA certification pathway, although it could still support a separate patent-infringement action against commercial manufacture or sale.

What generic entry risks exist?

The patent creates a focused risk for generic or follow-on transdermal products that copy the same construction. The risk is lower for products using different adhesion technology.

Design option	Likely risk under claim 1
Silicone matrix directly on backing without anchor layer	Lower literal risk
Acrylic adhesive matrix	Lower literal risk
Polyisobutylene adhesive system	Lower literal risk
Silicone anchor layer over 10 micrometers	Potentially outside literal thickness limitation
Silicone anchor layer below 10 micrometers with claimed chemistry	High literal risk
Non-silicone primer	Lower literal risk
Separate membrane-controlled system	Depends on whether the claimed polymer layer remains present
Drug-loaded anchor layer	May avoid claim 8, but not necessarily claim 1
PET backing plus silicone anchor and silicone matrix	High risk profile

The less-than-10-micrometer limitation is a significant design-around target. A product at or above 10 micrometers may avoid literal infringement of claim 1, but measurement methodology, manufacturing tolerances, nonuniform coating thickness, and the doctrine of equivalents would remain relevant.

How does Patent 10,034,841 compare with a conventional silicone patch?

Feature	Conventional silicone matrix patch	Claimed system
Backing	Present	Present
Silicone drug matrix	Often present	Required
Separate anchor layer	Often absent	Required
Anchor chemistry	Not necessarily specified	Vinyl/Si-H organopolysiloxane system
Anchor thickness	Not necessarily controlled below 10 micrometers	Required below 10 micrometers
Drug in anchor	May occur	Claim 8 specifies no active absorption
Release liner	Common	Covered by claims 7 and 11
Adhesive overhang control	Product-dependent	Addressed by claim 9

The patent is strongest against products that reproduce the claimed interface architecture to improve adhesion between a polar backing and a silicone drug matrix.

Is there biosimilar risk?

No conventional biosimilar issue arises from the claims. The patent concerns a transdermal delivery system, generally associated with small-molecule drug products rather than biologic reference products. The relevant competitors would normally be generic-drug applicants, authorized generics, contract manufacturers, or branded transdermal-product developers.

A biologic delivered through a patch would raise separate regulatory and formulation questions, but the claims themselves do not create biosimilar-specific rights.

What litigation, Paragraph IV challenges, or settlements affect the patent?

The supplied claim set establishes no litigation, Paragraph IV certification, license, or settlement. The patent number alone does not establish that a marketed product is covered, that the patent is Orange Book-listed, or that an ANDA applicant has challenged it.

The practical litigation question is whether an accused patch contains the claimed sub-10-micrometer crosslinked silicone anchor layer. That issue would likely require technical discovery rather than reliance on product labeling.

How strong is the patent estate?

The individual claim set has moderate structural strength and limited drug-specific breadth.

Factor	Assessment
Drug coverage	Broad because no specific active ingredient is required
Structural coverage	Narrow because of the anchor-layer and thickness limitations
Design-around potential	Meaningful through non-silicone primers, different adhesive systems, or altered layer thickness
Detectability	Moderate; chemistry and thickness may require destructive testing
Orange Book leverage	Not established from the supplied record
Biosimilar relevance	Low
Manufacturing relevance	Moderate to high
Product-specific blocking power	Depends on the target patch architecture
Platform value	Potentially broad across silicone-based transdermal products

Key Takeaways

U.S. Patent 10,034,841 is a transdermal-system patent, not a patent on a specific active pharmaceutical ingredient.
Claim 1 requires a backing layer, a separate siliconized anchor layer, and a drug-containing silicone adhesive polymer layer in that order.
The anchor layer must use vinyl-functional and Si-H-functional organopolysiloxanes and be less than 10 micrometers thick.
Claims 2 through 11 add common commercial materials and construction details, including PET backing, polysiloxane adhesives, release liners, drug-free anchor layers, and no adhesive overhang.
The patent presents its greatest risk to silicone matrix patches that use an ultrathin silicone primer or anchor between the backing and drug layer.
Acrylic, polyisobutylene, non-silicone primer, and direct-to-backing designs offer the clearest design-around pathways.
The claims do not establish FDA exclusivity, Orange Book listing, Paragraph IV activity, biosimilar protection, litigation, licensing, or settlement rights.
Patent expiration must be calculated from the underlying application and applicable patent-term adjustments, not from the grant date alone.

FAQs

Can a patch infringe U.S. Patent 10,034,841 without using the same drug?

Yes. The claims do not require a particular active ingredient. A different drug can still infringe if the patch has every claimed structural and chemical limitation.

Does a silicone release liner alone create infringement?

No. A release liner is addressed in claims 7 and 11, but claim 1 requires the separate siliconized anchor layer and its specified crosslinked organopolysiloxane chemistry.

Can increasing the anchor-layer thickness avoid infringement?

An anchor layer consistently at or above 10 micrometers may avoid literal infringement of the less-than-10-micrometer limitation. The result depends on the measured thickness and any equivalency analysis.

Is claim 8 important for generic patch developers?

Yes. Claim 8 requires an anchor layer that absorbs no active ingredient. It may distinguish a drug-free silicone primer from an intermediate layer that functions as a drug reservoir or absorbs drug during manufacture or storage.

Does this patent block an ANDA automatically?

No. An ANDA consequence depends on whether the patent is listed against the relevant reference product and whether the proposed generic product practices the claims. A patent covering a transdermal platform is not automatically an Orange Book-listed patent.

References

U.S. Patent No. 10,034,841, “Transdermal therapeutic system,” issued July 31, 2018. United States Patent and Trademark Office.
35 U.S.C. §§ 154, 156.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). FDA.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2004 044 578	Sep 13, 2004

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	050621	⤷ Start Trial
Australia	2005284436	⤷ Start Trial
Brazil	PI0515270	⤷ Start Trial
Canada	2578534	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,034,841

Summary for Patent: 10,034,841